BioCentury
ARTICLE | Financial News

Flagship-backed Kaleido raises $101M series C round

June 29, 2018 6:29 PM UTC

Microbiome company Kaleido Biosciences Inc. (Bedford, Mass.) raised $101 million in a series C round. Founding investor Flagship Pioneering participated, as did several new investors including an affiliate of Abu Dhabi Investment Authority, Fidelity, Invus and Rock Springs Capital. Flagship launched Kaleido in 2015; it emerged from stealth last fall (see “Flagship Pioneering Unveils Microbiome-Focused Company”).

Kaleido CEO Mike Bonney told BioCentury the company is developing compounds that affect the microbiome’s environment to the advantage or disadvantage of certain bacteria. Through this approach, the company has been able to upregulate biome-produced metabolites sixfold to sevenfold, or downregulate metabolites to low single-digit levels compared with an unaffected biome, he said...

BCIQ Company Profiles

Kaleido Biosciences Inc.